Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-ICE and High-Dose Cyclophosphamide for PET-positive DLBCL
NCT00809341Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2009
- Primary completion
- Apr 2014
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jan 2009; status: terminated.
02
Drugs
cyclophosphamide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT00809341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00809341.